Exhibit 99.1 Monetization Updates Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Lindsay A. Rosenwald, M.D., Fortress' Chairman, President and Chief Executive Officer, said, "Fortress entered 2025 with strong momentum following a transformational fourth quarter marked by the U.S. Food and Drug Administration ("FDA") approvals of Emrosi™ and UNLOXCYT™, and the acce ...